

Subconjunctival delivery of dorzolamide-loaded poly(ether-anhydride) microparticles  
produces sustained lowering of intraocular pressure in rabbits

Jie Fu<sup>1,2</sup>, Fengying Sun<sup>1,2</sup>, Wenhua Liu<sup>1,2</sup>,

Yanfei Liu<sup>1,2†</sup>, Manasee Gedam<sup>1,2</sup>, Qi Hu<sup>1,2</sup>, Colleen Fridley<sup>2</sup>, Harry A. Quigley<sup>1-3</sup>, Justin

Hanes<sup>1,2\*</sup> and Ian Pitha<sup>1-3\*</sup>


<sup>1</sup> Department of Ophthalmology, <sup>2</sup>Center for Nanomedicine, <sup>3</sup>Glaucoma Center of  
Excellence, The Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Correspondence: Ian Pitha, Center for Nanomedicine at the Wilmer Eye Institute, Johns  
Hopkins University, 400 N. Broadway, Robert H. and Clarice Smith Bldg., 6027, Baltimore,  
MD 21231, USA.


*E-mail address:* [ipitha1@jhmi.edu](mailto:ipitha1@jhmi.edu)

<sup>†</sup> Present address: Department of Pharmaceutical Engineering, School of Chemistry  
and Chemical Engineering, Central South University, Changsha 410083, Hunan, China  
E-mail: [yfliu69@163.com](mailto:yfliu69@163.com)


(a)




(b)



(c)



(d)



**Supplemental Figure 1. IOP after subconjunctival injection of DPP.** Subconjunctival injection of DPP (A, circles) versus control, untreated eyes (A, diamonds) (n=7). Blank microparticles without dorzolamide (PEG<sub>3</sub>-PSA) (B, circles) versus untreated eyes (B, diamonds) (n=4). Topical application of 2% dorzolamide drops (C, circles) versus untreated, fellow eyes (C, diamonds)(n=5). Repeat injection of DPP (D, circles) versus untreated, fellow eyes (D, diamonds) (n=3). \*  $P < 0.05$ .